Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1Phase 2/3 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Burkitt Lymphoma 1

Interventions

Rituximab 4Etoposide 4Whole-Body Irradiation 2Gemcitabine 2Cyclophosphamide 2umbralisib 1ublituximab 1rasburicase 1pegfilgrastim 1fludarabine phosphate 1fludarabine 1epratuzumab 1aldesleukin 1Trimethoprim, Sulfamethoxazole Drug Combination 1Thiotepa 1Radioimmunodetection 1Prednisone 1Oxaliplatin 1Nivolumab 1Melphalan 1Leucovorin 1Lenalidomide 1Immunoglobulins, Intravenous 1Hizentra 1Filgrastim 1Doxorubicin 1Cytarabine 1Ciprofloxacin 1Carboplatin 1Busulfan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Lymphoma, Non-Hodgkin × epratuzumab × Clear all
NCT00003338 2021-08-16

Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma

Gilead Sciences

Phase 2/3 Unknown
60 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡